Cornercap Investment Counsel Inc. Sells 781 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cornercap Investment Counsel Inc. trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,409 shares of the medical equipment provider’s stock after selling 781 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Hologic were worth $1,183,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of HOLX. Cerity Partners LLC raised its holdings in shares of Hologic by 50.6% during the third quarter. Cerity Partners LLC now owns 59,884 shares of the medical equipment provider’s stock valued at $4,878,000 after purchasing an additional 20,132 shares during the period. Loomis Sayles & Co. L P raised its stake in Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 183 shares during the period. Private Trust Co. NA boosted its holdings in Hologic by 19.6% in the third quarter. Private Trust Co. NA now owns 1,166 shares of the medical equipment provider’s stock worth $95,000 after acquiring an additional 191 shares in the last quarter. Bank of Montreal Can grew its stake in Hologic by 3.9% in the third quarter. Bank of Montreal Can now owns 492,210 shares of the medical equipment provider’s stock valued at $39,780,000 after acquiring an additional 18,532 shares during the period. Finally, Dai ichi Life Insurance Company Ltd acquired a new position in shares of Hologic during the third quarter worth approximately $757,000. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 1.6 %

HOLX opened at $61.32 on Friday. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a market cap of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average of $65.24 and a 200 day moving average of $73.35.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on HOLX shares. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective for the company. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.